Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of methyl berberine as a jnk2 kinase inhibitor and in the treatment of psoriasis

A technology for methyl berberine and psoriasis, applied in the field of methyl berberine, which can solve the problems of restricting wide application, many active ingredients, and unclear mechanism of action

Active Publication Date: 2022-05-03
朱峰
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the pharmacological effects of Coptidis Rhizome are clear, its active ingredients are many, its molecular targets are unknown, and its mechanism of action is unclear, which limits its wide application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of methyl berberine as a jnk2 kinase inhibitor and in the treatment of psoriasis
  • Use of methyl berberine as a jnk2 kinase inhibitor and in the treatment of psoriasis
  • Use of methyl berberine as a jnk2 kinase inhibitor and in the treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 The binding ability and inhibitory activity of methyl berberine and JNK2 kinase

[0060] 1. Determination of the binding constant Kd of methyl berberine and JNK2 by micro-thermophoresis (MST)

[0061] (1) Purchase pGSTag Flag Jnk2a2 plasmid from addgene company, transfer it into BL21 bacteria for expression, culture at 37°C, induce with ITPG for 4 hours, separate and purify GST-JNK2a2 protein with GSH-beads.

[0062] (2) GST-JNK2a2 recombinant protein according to Monolith NT TM Protein Labeling Kit RED (Cat#L001) was used for labeling. Methyl berberine was configured into 50mM mother solution with DMSO, and was diluted with 20mM HEPES (pH7.4) assay solution containing 5% DMSO. The highest concentration was 2mM, and the lowest concentration was 0.14nM. A total of 16 diluted working solutions. GST-JNK2a2 protein at a concentration of 869.6nM was added to each working solution, and the equilibrium dissociation constant Kd was measured on a microcalorometer. T...

Embodiment 2

[0065] Example 2 Observing the effect and molecular mechanism of methyl berberine on inhibiting psoriasis in a psoriasis cell model

[0066] 1. MTT method to determine the concentration of 80% HaCat cell survival after the addition of methyl berberine

[0067] HaCat cells were digested and counted, and 7000 cells were inoculated into each well of a 96-well plate. After 24 hours, different concentrations of methyl coptisine (0 μM, 0.4 μM, 2 μM, 10 μM, 50 μM, 250 μM, 1250 μM) were added to 10 wells at each concentration. 24h and 48h after adding the drug, add 100μl of 0.5mg / ml MTT to each well, incubate at 37°C for 4 hours, discard the MTT solution, add 150μl DMSO, shake well to completely dissolve the crystals in the well, and measure the wavelength at 490nm with a microplate reader The absorbance value was used to analyze cell viability. Take 80% HaCat cell survival rate as the drug safety concentration, that is, 12.5μM, IC 50 = 175 μM.

[0068] 2. Establish a psoriasis cel...

Embodiment 3

[0070] Example 3 Methyl coptisine reduces the clinical manifestations and pathological changes of psoriasis induced by imiquimod (IMQ)

[0071] 1. Establishment of animal models of psoriasis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of methyl berberine as a JNK2 kinase inhibitor. The methyl berberine can specifically bind to the JNK2 kinase and the two have strong binding ability, and at the same time inhibit the activity of JNK2 in a dose-dependent manner. Methyl berberine has good therapeutic activity on psoriasis, which is closely related to methyl berberine inhibiting the activation of JNK and STAT3 signaling pathways and the expression of psoriasis marker molecule S1007, so it can be used as an active ingredient in the preparation of Medicines to treat psoriasis.

Description

technical field [0001] The present invention relates to the new use of methyl berberine, especially the new use as a JNK2 kinase inhibitor. The present invention also relates to the use of methyl berberine in the preparation of medicines for treating psoriasis and a medicine for treating psoriasis . Background technique [0002] c-jun N-terminal kinase [c-jun N-terminal kinases (JNK)] was first defined as stress-activated protein kinases [stress-activated protein kinases (SAPK)], is a serine threonine kinase, belongs to the mitogen Activated protein kinase [mitogen-activated protein kinase (MAPK)] family member. Mammalian JNKs are encoded by three different genes, namely JNK1, JNK2, and JNK3. After alternative splicing, there are more than ten kinds of protein products, with molecular weights ranging from 46kDa to 55kDa[1]. JNK1 and JNK2 are expressed in most tissues, while JNK3 expression is mainly restricted to the brain, heart and testis. The different distribution of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4375A61K36/718A61P17/06
CPCA61K31/4375A61K36/718A61K9/0014A61P17/06
Inventor 朱峰段秋红路慧马腾飞倪小芳
Owner 朱峰
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com